JP2020023549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020023549A5 JP2020023549A5 JP2019191044A JP2019191044A JP2020023549A5 JP 2020023549 A5 JP2020023549 A5 JP 2020023549A5 JP 2019191044 A JP2019191044 A JP 2019191044A JP 2019191044 A JP2019191044 A JP 2019191044A JP 2020023549 A5 JP2020023549 A5 JP 2020023549A5
- Authority
- JP
- Japan
- Prior art keywords
- naca
- therapeutic
- prophylactic agent
- agent according
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- UJCHIZDEQZMODR-BYPYZUCNSA-N (2r)-2-acetamido-3-sulfanylpropanamide Chemical compound CC(=O)N[C@@H](CS)C(N)=O UJCHIZDEQZMODR-BYPYZUCNSA-N 0.000 claims 12
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 230000000069 prophylactic effect Effects 0.000 claims 9
- 230000001225 therapeutic effect Effects 0.000 claims 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 201000004569 Blindness Diseases 0.000 claims 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 229960001563 acetylcysteine amide Drugs 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960001305 cysteine hydrochloride Drugs 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 239000008185 minitablet Substances 0.000 claims 1
- 230000004297 night vision Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 235000010388 propyl gallate Nutrition 0.000 claims 1
- 239000000473 propyl gallate Substances 0.000 claims 1
- 229940075579 propyl gallate Drugs 0.000 claims 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 claims 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 claims 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims 1
- 229940001584 sodium metabisulfite Drugs 0.000 claims 1
- 235000010262 sodium metabisulphite Nutrition 0.000 claims 1
- 235000010265 sodium sulphite Nutrition 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021147283A JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2023127716A JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2025126989A JP2025160381A (ja) | 2014-11-07 | 2025-07-30 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076594P | 2014-11-07 | 2014-11-07 | |
| US62/076,594 | 2014-11-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544552A Division JP2017533969A (ja) | 2014-11-07 | 2015-11-06 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021147283A Division JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2023127716A Division JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020023549A JP2020023549A (ja) | 2020-02-13 |
| JP2020023549A5 true JP2020023549A5 (https=) | 2020-08-06 |
Family
ID=55909913
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544552A Pending JP2017533969A (ja) | 2014-11-07 | 2015-11-06 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2019191044A Pending JP2020023549A (ja) | 2014-11-07 | 2019-10-18 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2021147283A Pending JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2023127716A Pending JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2025126989A Pending JP2025160381A (ja) | 2014-11-07 | 2025-07-30 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544552A Pending JP2017533969A (ja) | 2014-11-07 | 2015-11-06 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021147283A Pending JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2023127716A Pending JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2025126989A Pending JP2025160381A (ja) | 2014-11-07 | 2025-07-30 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12472157B2 (https=) |
| EP (2) | EP3214934A4 (https=) |
| JP (5) | JP2017533969A (https=) |
| KR (3) | KR20170109527A (https=) |
| CN (2) | CN108498495A (https=) |
| AU (5) | AU2015342831B2 (https=) |
| BR (1) | BR112017009584A2 (https=) |
| CA (1) | CA2967327C (https=) |
| HK (1) | HK1252822A1 (https=) |
| RU (1) | RU2711913C2 (https=) |
| WO (2) | WO2016073931A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10752593B2 (en) | 2018-12-28 | 2020-08-25 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| US12472157B2 (en) | 2014-11-07 | 2025-11-18 | Nacuity Pharmaceuticals, Inc. | Treatment of retinitis pigmentosa with n-acetylcysteine amide |
| WO2016077467A1 (en) | 2014-11-11 | 2016-05-19 | The Johns Hopkins University | Biomarkers useful in the treatment of subjects having diseases of the eye |
| US11091433B2 (en) | 2017-09-20 | 2021-08-17 | Nacuity Pharmaceutials, Inc. | Method for preparation of N-acetyl cysteine amide and derivatives thereof |
| EP3684756A4 (en) | 2017-09-20 | 2020-10-28 | NaCuity Pharmaceuticals, Inc. | SYNTHESIS OF N-ACETYLCYSTEIN AMIDE AND ITS DERIVATIVES |
| US11548851B2 (en) | 2017-09-20 | 2023-01-10 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide and derivatives thereof |
| US20190135741A1 (en) | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| US20190151271A1 (en) * | 2017-11-21 | 2019-05-23 | The Johns Hopkins University | Compositions and methods for treatment of eye diseases |
| CA3104209A1 (en) * | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| CN109096161B (zh) * | 2018-08-24 | 2020-10-27 | 武汉远大弘元股份有限公司 | 一种n-乙酰半胱氨酸的制备方法 |
| US10807973B2 (en) | 2018-12-28 | 2020-10-20 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| WO2020146660A1 (en) | 2019-01-11 | 2020-07-16 | Nacuity Pharmaceuticals, Inc. | N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis |
| EP3908341A4 (en) | 2019-01-11 | 2022-03-02 | NaCuity Pharmaceuticals, Inc. | TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA) |
| EP3908271A4 (en) | 2019-01-11 | 2022-10-26 | NaCuity Pharmaceuticals, Inc. | N-ACETYLCYSTEINE AMIDE (NACA) AND (2R,2R')-3,3'-DISULFANDIYL BIS-(2-ACETAMIDOPROPANAMIDE) (DINACA) FOR THE PREVENTION AND TREATMENT OF RADIATION DERMATITIS AND SKIN LIGHTENING AND IMPROVEMENT |
| AU2021209953B2 (en) * | 2020-01-24 | 2024-08-22 | Nacuity Pharmaceuticals, Inc. | Prodrug for the treatment of disease and injury of oxidative stress |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3252866A (en) | 1965-06-28 | 1966-05-24 | Mead Johnson & Co | 2-hydrocarbon substituted-amido mercaptopropionamides in hair waving compositions and processes |
| US5874468A (en) | 1996-12-26 | 1999-02-23 | Yissum | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| US6420429B1 (en) | 1997-12-23 | 2002-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| US20030027745A1 (en) | 2001-06-13 | 2003-02-06 | Repine John E. | Diagnostic and prognostic method for evaluating ocular inflammation and oxidative stress and the treatment of the same |
| BE1014949A3 (fr) | 2001-08-14 | 2004-07-06 | Probiox | Procede de detection de stress oxydant et trousse pour sa mise en oeuvre. |
| US20060211628A1 (en) | 2002-08-02 | 2006-09-21 | Daphne Atlas | Treatment of multiple sclerosis with brain targeted anti oxidant compounds |
| US7795203B2 (en) | 2002-09-30 | 2010-09-14 | Babizhayev Mark A | Method for topical treatment of eye disease and composition and device for said treatment |
| JP2005350405A (ja) | 2004-06-11 | 2005-12-22 | Shiseido Co Ltd | 重合抑制剤および即時型黒化防止用皮膚外用剤 |
| US8993627B2 (en) | 2005-04-21 | 2015-03-31 | Sentient Lifesciences, Inc. | N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress |
| CN101232877A (zh) * | 2005-04-21 | 2008-07-30 | 格伦·A·戈尔茨坦 | 治疗与氧化应激有关的疾病和病症的n-乙酰半胱氨酸酰胺（nac酰胺） |
| US20090234011A1 (en) * | 2005-04-21 | 2009-09-17 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
| JP4840804B2 (ja) | 2006-01-20 | 2011-12-21 | 学校法人慶應義塾 | 酸化ストレスの判定方法 |
| WO2010048716A1 (en) | 2008-10-29 | 2010-05-06 | Pacific Therapeutics Ltd. | Composition and method for treating fibrosis |
| US20120150029A1 (en) | 2008-12-19 | 2012-06-14 | University Of Miami | System and Method for Detection and Monitoring of Ocular Diseases and Disorders using Optical Coherence Tomography |
| US9173423B2 (en) | 2009-07-31 | 2015-11-03 | The Iams Company | Animal food kibble with electrostatically adhered dusting |
| WO2011044230A2 (en) | 2009-10-06 | 2011-04-14 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions |
| EP2397125A1 (en) | 2010-06-15 | 2011-12-21 | Histocell, S.L. | Antioxidant composition |
| US20120142550A1 (en) | 2010-12-06 | 2012-06-07 | Zehnder James L | Vanin 1 as a Peripheral Blood Oxidative Stress Sensor |
| WO2013138744A1 (en) | 2012-03-16 | 2013-09-19 | M. Alphabet 1, Llc | Compositions for the treatment of skin disorders |
| CA2871774C (en) * | 2012-04-26 | 2021-05-18 | Sentient Lifesciences, Inc. | Use of n-acetylcysteine amide in the treatment of disease and injury |
| EP2928562A4 (en) | 2012-12-06 | 2016-06-22 | Stealth Peptides Int Inc | PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE |
| US20150328337A1 (en) | 2012-12-19 | 2015-11-19 | The Johns Hopkins University | Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase |
| US9763902B2 (en) | 2014-03-28 | 2017-09-19 | Nacuity Pharmaceuticals, Inc | Method for preparation of N-acetyl cysteine amide |
| US12472157B2 (en) | 2014-11-07 | 2025-11-18 | Nacuity Pharmaceuticals, Inc. | Treatment of retinitis pigmentosa with n-acetylcysteine amide |
| WO2016077467A1 (en) | 2014-11-11 | 2016-05-19 | The Johns Hopkins University | Biomarkers useful in the treatment of subjects having diseases of the eye |
| JP7418958B2 (ja) | 2016-03-17 | 2024-01-22 | チオジェネシス セラピューティクス， インコーポレイテッド | システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療 |
| EP3684756A4 (en) | 2017-09-20 | 2020-10-28 | NaCuity Pharmaceuticals, Inc. | SYNTHESIS OF N-ACETYLCYSTEIN AMIDE AND ITS DERIVATIVES |
| JP7208982B2 (ja) | 2017-09-20 | 2023-01-19 | チオジェネシス セラピューティクス， インコーポレイテッド | システアミン感受性障害の治療方法 |
| WO2019060704A1 (en) | 2017-09-22 | 2019-03-28 | University Of Florida Research Foundation | DEVICES AND METHODS FOR REDUCTION OF IN VIVO CYSTINE CRYSTALS |
| US20190135741A1 (en) | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| WO2019097434A1 (en) | 2017-11-17 | 2019-05-23 | Mahmood Piraee | Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders |
| US20190151271A1 (en) | 2017-11-21 | 2019-05-23 | The Johns Hopkins University | Compositions and methods for treatment of eye diseases |
| CN108618993B (zh) | 2018-07-16 | 2021-07-27 | 广东格烯生物科技股份有限公司 | 一种美白组合物及其制备方法和应用 |
| WO2020102810A1 (en) | 2018-11-16 | 2020-05-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Thermoresponsive gel eye drop for ocular delivery of cysteamine |
| EP3908341A4 (en) | 2019-01-11 | 2022-03-02 | NaCuity Pharmaceuticals, Inc. | TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA) |
| WO2020146660A1 (en) | 2019-01-11 | 2020-07-16 | Nacuity Pharmaceuticals, Inc. | N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis |
| EP3908271A4 (en) | 2019-01-11 | 2022-10-26 | NaCuity Pharmaceuticals, Inc. | N-ACETYLCYSTEINE AMIDE (NACA) AND (2R,2R')-3,3'-DISULFANDIYL BIS-(2-ACETAMIDOPROPANAMIDE) (DINACA) FOR THE PREVENTION AND TREATMENT OF RADIATION DERMATITIS AND SKIN LIGHTENING AND IMPROVEMENT |
-
2015
- 2015-11-06 US US15/523,665 patent/US12472157B2/en active Active
- 2015-11-06 WO PCT/US2015/059589 patent/WO2016073931A1/en not_active Ceased
- 2015-11-06 KR KR1020177015227A patent/KR20170109527A/ko not_active Ceased
- 2015-11-06 KR KR1020227009489A patent/KR20220039853A/ko not_active Ceased
- 2015-11-06 RU RU2017119230A patent/RU2711913C2/ru active
- 2015-11-06 US US15/524,636 patent/US20180296503A1/en not_active Abandoned
- 2015-11-06 BR BR112017009584A patent/BR112017009584A2/pt not_active Application Discontinuation
- 2015-11-06 KR KR1020237036499A patent/KR20230152177A/ko not_active Ceased
- 2015-11-06 AU AU2015342831A patent/AU2015342831B2/en active Active
- 2015-11-06 EP EP15857309.7A patent/EP3214934A4/en not_active Ceased
- 2015-11-06 CA CA2967327A patent/CA2967327C/en active Active
- 2015-11-06 EP EP21217485.8A patent/EP4000612A1/en active Pending
- 2015-11-06 JP JP2017544552A patent/JP2017533969A/ja active Pending
- 2015-11-06 CN CN201810698779.7A patent/CN108498495A/zh active Pending
- 2015-11-06 WO PCT/US2015/059418 patent/WO2016073829A2/en not_active Ceased
- 2015-11-06 CN CN201580072224.6A patent/CN107426997A/zh active Pending
-
2018
- 2018-09-20 HK HK18112150.1A patent/HK1252822A1/zh unknown
-
2019
- 2019-10-18 JP JP2019191044A patent/JP2020023549A/ja active Pending
- 2019-11-07 AU AU2019261762A patent/AU2019261762B2/en active Active
-
2021
- 2021-09-06 AU AU2021225263A patent/AU2021225263B2/en active Active
- 2021-09-10 JP JP2021147283A patent/JP2021193119A/ja active Pending
-
2023
- 2023-08-04 JP JP2023127716A patent/JP2023145734A/ja active Pending
-
2024
- 2024-01-24 AU AU2024200436A patent/AU2024200436A1/en not_active Abandoned
-
2025
- 2025-07-30 JP JP2025126989A patent/JP2025160381A/ja active Pending
-
2026
- 2026-01-05 AU AU2026200033A patent/AU2026200033A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020023549A5 (https=) | ||
| JP2017533969A5 (https=) | ||
| JP2023145734A5 (https=) | ||
| CA2388609A1 (en) | Oxcarbazepine formulations for administration with or without food | |
| WO2006102446A3 (en) | Multi-particulate, modified-released colonic composition | |
| RU2017119230A (ru) | Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом | |
| RU2010147287A (ru) | Комбинированная композиция | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| AR028299A1 (es) | Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes. | |
| CA2240329A1 (en) | Improved delivery of multiple doses of medications | |
| CO4940409A1 (es) | Tableta cubierta con pelicula para seguridad mejorada del tracto gastrointestinal superior | |
| IT1271495B (it) | Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil-1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi | |
| DE60020551D1 (de) | Orale formulierung zur verabreichung in den ileum enthaltend einen hemmstoff des ileum-gallensäuretransports | |
| WO2003047519A3 (en) | 'compressed annular tablet with molded triturate tablet for oral and intraoral' | |
| JP2006504795A5 (https=) | ||
| JP2012533565A5 (https=) | ||
| ECSP045409A (es) | Composiciones y metodos para dosificar liposomas de ciertos tamaños a fin de tratar o prevenir enfermedades. | |
| UA85359C2 (ru) | Таблетка, содержащая гранулированный материал с kmd-3213 | |
| ME02474B (me) | Terapijski režimi | |
| CA2411882A1 (en) | Solid valsartan pharmaceutical compositions | |
| JP2005525329A5 (https=) | ||
| RU2011111792A (ru) | Применение парацетамола и ибупрофена в лечении | |
| HUP0203148A2 (hu) | Mirtazapint tartalmazó orálisan dezintegrálódó készítmény | |
| JPWO2020146666A5 (https=) | ||
| SG145717A1 (en) | Composition for releasing a weak base for an extended period of time |